Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Psychopharmacology (Berl). 2017 Jun 30;234(18):2761–2776. doi: 10.1007/s00213-017-4673-y

Figure 1. Systemic administration of RTIOX-276 decreases high-effort responding for cocaine.

Figure 1

(A) Average number of infusions across the 6-hour self-administration session for vehicle, 5, 10, and 20 mg/kg RTIOX-276 treatment (n=7). The dotted line represents the end of the low-effort consumption phase and the beginning of the high-effort appetitive phase. Shaded region represents standard error of the mean. (B) Effect of HCRTr1 blockade on the number of infusions received by the end of consumption phase. One-way repeated measures ANOVA revealed no significant difference between vehicle and RTIOX-276 treatments. (C) Effect of HCRTr1 blockade on infusion rate across the consumption phase. One-way repeated measures ANOVA revealed no effect of vehicle or RTIOX-276 on infusion rate. (D) Effect of HCRTr1 blockade on breakpoint. One-way repeated measures ANOVA revealed a significant effect of RTIOX-276 treatment on breakpoints (F(3,24) = 6.803, p = 0.0018). (E) Effect of HCRTr1 blockade on total lever presses. One-way repeated measures ANOVA revealed a significant effect of RTIOX-276 treatment on total lever presses (F(3,24) = 10.04, p < 0.001). Grouped data are presented as mean ± SEM. Dunnet’s post hoc tests: *p < 0.05, **p < 0.01.